Language

Investor Relations

The Company is listed on AktieTorget since May 2015. The product portfolio contains a CE-marked medical device for diagnostics of peripheral nerve damage in the hands. The instrument is used clinically by several Occupational Health Care providers in Sweden and by all clinics of Occupational and Environmental Medicine in Sweden and Norway.

The company is currently working to expand its product portfolio with a foot instrument for the diagnosis of peripheral nerve damage in the feet of people with diabetes, a population estimated at over 415 million people worldwide.

The development of the new foot instrument is planned to be completed during the last quarter of 2017 when the new instrument will be ready for launch.